USFDA okays Xeris Pharma glucagon pen Gvoke to treat low blood sugar

Xeris Pharma's Gvoke, a glucagon pen is a pre-filled device with a liquid stable form of glucagon.

U.S: The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's glucagon pen that aims to treat severe low sugar levels in diabetes patients, the drugmaker said on Tuesday.

The condition, called hypoglycemia, can cause acute cognitive impairment. It can occur multiple times a month, can also result in heart disease, seizure and coma in its severe form.

Read Also: Abbott hits a record high as blood sugar monitoring device- FreeStyle Libre 2 fuels profit

Gvoke, Xeris' glucagon pen is a pre-filled device with a liquid stable form of glucagon.

Read Also: Apple watches to have Glucose tracker to monitor blood sugar constantly, CEO seen testing Prototype